Gain Therapeutics Inc
GANX
Get informed when a big investor buys or sells
+ FollowMarket Cap$83.18M
Close$
$0.61
65.9% downside
Current Fair Value
65.9% downsideOvervalued by 65.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $83.18 Million |
|---|---|
| Enterprise Value | $66.93 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.61 |
| Beta | 0.15 |
| Outstanding Shares | 42,230,248 |
Return
| Return on Equity | -151.64% |
|---|---|
| Return on Assets | -113.35% |
| Return on Invested Capital | -132.27% |
Valuation & Multiples
| P/E Ratio | -3.88 |
|---|---|
| PEG | -16.28 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -3.41 |
| Enterprise Value to Net Income | -4 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.02 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 19, 2026
EPS Estimate
$-0.14
Average shareholder expectationRevenue Estimate
$33,333
Average shareholder expectationNext Earnings Call
Expected Date
August 6, 2026
EPS Estimate
$-0.15
Average shareholder expectationRevenue Estimate
$33,333
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.3435▼ 14.55% |
|---|---|
| Total Calls | 91,400▲ 11.46% |
| Total Puts | 31,400▼ 21.70% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 24.86%▲ 1.83% |
|---|---|
| Total Invested | $15.82M▼ 39.02% |
| Investors Holding | 46▼ 6.00% |
ESG Score
No data
About Gain Therapeutics Inc
16 employeesGain Therapeutics, Inc. is redefining drug discovery with its See-Tx™ target identification platform. By identifying and optimizing allosteric binding sites that have never before been targeted, Gain is unlocking new treatment options fo...